Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

When should sarcoidosis be treated?

R C Young, R E Rachal, C L Cowan

    Journal of the National Medical Association
    |September 1, 1986
    PubMed
    Summary
    This summary is machine-generated.

    Sarcoidosis treatment is essential for the 20% of patients with chronic disease. Prompt identification of active sarcoidosis using key tests guides therapy decisions for better patient outcomes.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Ocular Sarcoidosis.

    Journal of the National Medical Association·2010
    Same author

    Pulmonary disability in former Appalachian coal miners.

    Journal of the National Medical Association·1996
    Same author

    Disability in geriatric depression.

    The American journal of psychiatry·1996
    Same author

    Brachioradialis muscle inserting on the third metacarpal.

    Journal of anatomy·1996
    Same author

    Intra-and intercellular calcium waves in cultured human myometrium.

    Journal of muscle research and cell motility·1996
    Same author

    Recovery in geriatric depression.

    Archives of general psychiatry·1996
    Same journal

    Perioperative outcomes: Transforming healthcare.

    Journal of the National Medical Association·2026
    Same journal

    The intersection of infectious diseases and cardiovascular disease in Africa: A narrative review.

    Journal of the National Medical Association·2026
    Same journal

    Atrial fibrillation in chronic heart failure: prevalence and one-year outcome in the Ibadan chronic heart failure project.

    Journal of the National Medical Association·2026
    Same journal

    Corrigendum to ``Medical student perspectives of leadership development in community engagement'' [In Press].

    Journal of the National Medical Association·2026
    Same journal

    Ethno-racial trauma and well-being in medical education: A scoping review of U.S. physician trainees and medical students.

    Journal of the National Medical Association·2026
    Same journal

    Cuts to medicaid and the affordable care act: Negative consequences for the black community.

    Journal of the National Medical Association·2026
    See all related articles

    Area of Science:

    • Pulmonology
    • Immunology
    • Dermatology

    Background:

    • Sarcoidosis affects approximately 20% of patients with chronic, unremitting disease requiring intervention.
    • Early identification of active sarcoidosis is crucial for initiating timely and effective treatment.
    • Disease activity assessment guides therapeutic decisions, distinguishing between active and inactive cases.

    Purpose of the Study:

    • To outline the diagnostic criteria for active sarcoidosis.
    • To detail the therapeutic strategies for managing chronic sarcoidosis.
    • To review the efficacy of various treatment options.

    Main Methods:

    • Assessment of disease activity using serum angiotensin converting enzyme levels, gallium 67 scans, and bronchoalveolar lavage.
    • Evaluation of vital organ system involvement, including ocular, pulmonary, central nervous system, cutaneous, and myocardial systems.

    Related Experiment Videos

  • Review of therapeutic interventions, including adrenocorticoids, chloroquine phosphate, oxyphenbutazone, and immunosuppressives.

    • Main Results:

    • Adrenocorticoids (methylprednisolone, prednisone, cortisol) are the primary treatment choice.
    • Alternate-day or low-dose steroid regimens are increasingly utilized.
    • Chloroquine phosphate is effective for cutaneous sarcoidosis; oxyphenbutazone shows comparable efficacy to prednisone.

    Conclusions:

    • Prompt treatment initiation for active sarcoidosis is essential.
    • Adrenocorticoids remain the cornerstone of therapy, with steroid-sparing strategies gaining traction.
    • Immunosuppressives and emerging agents like cyclosporine offer alternative or adjunctive treatment options for refractory cases.